Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025

Figure 2 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDimitrios MathiosNNNoushin NiknafsAAAkshaya V. Annapragada

Discussion

Loading...

Member takes

Overview

ARTEMIS–DELFI identifies brain cancer in patients and noncancer controls, indicating potential for clinical diagnostics.

Key Points

  • ARTEMIS–DELFI scores differentiate between brain tumors and noncancer individuals effectively.
  • Igliomas and metastatic brain tumors show significantly elevated ARTEMIS–DELFI scores compared to controls.
  • ROC analyses confirm strong specificity and sensitivity for brain cancer detection in both discovery and validation cohorts.
  • Findings support the use of ARTEMIS–DELFI as a promising tool in non-invasive brain cancer screening.

Cite This Study

Mathios et al. (2025) studied this question.

synapsesocial.com/papers/689a0f86e6551bb0af8d093bhttps://doi.org/10.1158/2159-8290.29819635
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figures S1-S10 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  2. 2Figure 3 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  3. 3Figure 4 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  4. 4Figure 5 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes2025
  5. 5Evaluation of Gemini Pro for primary site prediction in a real-world blinded cohort of 465 patients.2026